Lupin Limited has reported a remarkable financial performance for the quarter ending June 30, 2024. The pharmaceutical giant’s sales for Q1 FY2025 reached INR 55,143 million, marking a 12.7% increase from Q4 FY2024 and a 16.3% rise from Q1 FY2024. The company’s EBITDA surged by 27.5% quarter-on-quarter to INR 13,088 million, a 48.9% year-on-year increase. […]
In a significant move within the pharmaceutical industry, Zydus Lifesciences Limited, renowned for its global lifesciences innovations, and Lupin Limited, a leading global pharma entity, have officially declared their collaboration. The two companies have established a licensing and supply agreement for the co-marketing of Saroglitazar Mg, a pivotal medication for the management of Non-Alcoholic Fatty […]
Global pharmaceutical powerhouse, Lupin Limited has announced the receipt of the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (U.S. FDA) for its Nagpur Unit-1 manufacturing facility, specializing in oral solid dosage forms. This significant milestone follows the facility’s latest inspection in July 2023, with the U.S. FDA granting it a […]
In a move that has set the pharmaceutical industry abuzz, global pharma titan Lupin Limited has revealed the acquisition of five key legacy brands, zeroing in on pivotal therapy areas like Gastroenterology, Urology, and Anti-infectives. This acquisition, inked with Menarini, encompassing both A. Menarini India Private Limited and A. Menarini Asia-Pacific Holdings Pte. Ltd., includes […]
In a strategic move to fortify its position in the pharmaceutical domain, global major Lupin Limited proclaimed its acquisition of coveted diabetes brands ONDERO and ONDERO MET from Boehringer Ingelheim International GmbH. These brands, which Lupin has been marketing since 2015 under a co-marketing arrangement, come with the added bonus of trademark rights. India grapples […]
Pharmaceutical giant Lupin Limited reported its Q1 FY2024 financial performance, indicating a gross profit of INR 31,013 million, up from INR 25,803 million in Q4 FY2023. The gross margin stands at 65.4%, while personnel cost and manufacturing expenses show notable changes compared to the previous quarter. Key Financial Highlights Operating Working Capital: INR 51,946 million […]
Lupin said that the US Food and Drug Administration (FDA) has concluded an inspection of the company’s bioresearch centre in Pune, Maharashtra. The inspection was completed without any observation, said the Indian pharma company. Lupin’s bioresearch centre carries out bioavailability/bioequivalence (BA/BE), pharmacokinetics/pharmacodynamics (PK/PD), in-vitro BE, and biosimilar studies. Nilesh Gupta — Lupin Managing Director said: […]
Lupin said that the US Food and Drug Administration (FDA) has wrapped up a pre-approval and GMP inspection of its API manufacturing plant in Visakhapatnam, Andhra Pradesh. The FDA inspection was undertaken from 6 March to 10 March 2023 and was completed without any observations. Nilesh Gupta — Lupin Managing Director said: “We are pleased […]
Indian pharmaceutical company Lupin announced that Dr. Shahin Fesharaki has been appointed as Global Chief Scientific Officer who will handle global research and development works across generics, branded, and specialty products. Vinita Gupta – Lupin CEO and Lupin MD Nilesh Gupta said: “We are very pleased to welcome Shahin to our leadership team. Shahin’s exceptional […]
Lupin Limited has entered into partnerships with Unitaid, the Clinton Health Access Initiative (CHAI), The Aurum Institute, and other global procurement agencies for supporting tuberculosis (TB) prevention treatment. According to the Indian pharma company, the TB prevention treatment will be launched in 138 countries, including several low-and middle-income countries that are faced with a large […]